Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSPO | P30536 | 3/20 | 0.36 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.32 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25538995 | 1.00 | TSPO (0.36) | TSPONPY5RMAPK14DNM1KDM4E | |
| SCHEMBL25539408 | 0.98 | TSPO (0.35) | TSPONPY5RMAPK14DNM1KDM4E | |
| SCHEMBL25539397 | 0.98 | TSPO (0.35) | TSPONPY5RMAPK14DNM1KDM4E | |
| SCHEMBL25538990 | 0.96 | TSPO (0.38) | TSPONPY5RMAPK14DNM1KDM4E | |
| SCHEMBL25539340 | 0.95 | L3MBTL1 (0.41) | TSPONPY5RMAPK14DNM1KDM4E | |
| SCHEMBL25539333 | 0.95 | L3MBTL1 (0.41) | TSPONPY5RMAPK14DNM1KDM4E | |
| SCHEMBL25539548 | 0.95 | MAPK14 (0.32) | TSPOMAPK14KDM4EATML3MBTL1 | |
| SCHEMBL25539000 | 0.95 | TSPO (0.38) | TSPONPY5RMAPK14DNM1KDM4E | |
| SCHEMBL25538972 | 0.95 | KDM4E (0.35) | MAPK14KDM4EATML3MBTL1HSD17B10 | |
| SCHEMBL25538963 | 0.95 | KDM4E (0.35) | MAPK14KDM4EATML3MBTL1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159570-A1 | LIGHT-EMITTING DEVICE INCLUDING HETEROCYCLIC COMPOUND, ELECTRONIC APPARATUS INCLUDING THE LIGHT-EMITTING DEVICE, AND THE HETEROCYCLIC COMPOUND | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-05-25 | — | — | US | disclosed |
| US-20230159570-A1 | LIGHT-EMITTING DEVICE INCLUDING HETEROCYCLIC COMPOUND, ELECTRONIC APPARATUS INCLUDING THE LIGHT-EMITTING DEVICE, AND THE HETEROCYCLIC COMPOUND | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159570-A1 | LIGHT-EMITTING DEVICE INCLUDING HETEROCYCLIC COMPOUND, ELECTRONIC APPARATUS INCLUDING THE LIGHT-EMITTING DEVICE, AND THE HETEROCYCLIC COMPOUND | CRY1, CYP1A1, NQO1 | TSPO 1897/4885NPY5R 3574/4885MAPK14 3606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.